BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fairhurst RA, Knoepfel T, Buschmann N, Leblanc C, Mah R, Todorov M, Nimsgern P, Ripoche S, Niklaus M, Warin N, Luu VH, Madoerin M, Wirth J, Graus-Porta D, Weiss A, Kiffe M, Wartmann M, Kinyamu-Akunda J, Sterker D, Stamm C, Adler F, Buhles A, Schadt H, Couttet P, Blank J, Galuba I, Trappe J, Voshol J, Ostermann N, Zou C, Berghausen J, Del Rio Espinola A, Jahnke W, Furet P. Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. J Med Chem 2020;63:12542-73. [PMID: 32930584 DOI: 10.1021/acs.jmedchem.0c01019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Deng W, Chen X, Jiang K, Song X, Huang M, Tu ZC, Zhang Z, Lin X, Ortega R, Patterson AV, Smaill JB, Ding K, Chen S, Chen Y, Lu X. Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors. ACS Med Chem Lett 2021;12:647-52. [PMID: 33859803 DOI: 10.1021/acsmedchemlett.1c00052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Nie W, Lu Y, Pan C, Gao J, Luo M, Du J, Wang J, Luo P, Zhu H, Che J, He Q, Dong X. Design, Synthesis, and Biological Evaluation of Quinazoline Derivatives with Covalent Reversible Warheads as Potential FGFR4 Inhibitors. Bioorganic Chemistry 2022. [DOI: 10.1016/j.bioorg.2022.105673] [Reference Citation Analysis]
3 Kasatkina SO, Geyl KK, Baykov SV, Novikov MS, Boyarskiy VP. “Urea to Urea” Approach: Access to Unsymmetrical Ureas Bearing Pyridyl Substituents. Adv Synth Catal 2022;364:1295-304. [DOI: 10.1002/adsc.202101490] [Reference Citation Analysis]
4 Lu X, Smaill JB, Patterson AV, Ding K. Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors. J Med Chem 2021. [PMID: 34962782 DOI: 10.1021/acs.jmedchem.1c01719] [Reference Citation Analysis]
5 Ornitz DM, Itoh N. New developments in the biology of fibroblast growth factors. WIREs Mech Dis 2022;:e1549. [PMID: 35142107 DOI: 10.1002/wsbm.1549] [Reference Citation Analysis]
6 Liu D, Liu H, Gan J, Zeng S, Zhong F, Zhang B, Zhang Z, Zhang S, Jiang L, Wang G, Chen Y, Kong FS, Fang W, Wang L. LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC. Front Pharmacol 2022;13:918317. [DOI: 10.3389/fphar.2022.918317] [Reference Citation Analysis]
7 Henry Blackwell J, Harris GR, Smith MA, Gaunt MJ. Modular Photocatalytic Synthesis of α-Trialkyl-α-Tertiary Amines. J Am Chem Soc 2021;143:15946-59. [PMID: 34551248 DOI: 10.1021/jacs.1c07402] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Gampe C, Verma VA. Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients. J Med Chem 2020;63:14357-81. [DOI: 10.1021/acs.jmedchem.0c01177] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
9 Shao M, Chen X, Yang F, Song X, Zhou Y, Lin Q, Fu Y, Ortega R, Lin X, Tu Z, Patterson AV, Smaill JB, Chen Y, Lu X. Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4. J Med Chem 2022. [PMID: 35271262 DOI: 10.1021/acs.jmedchem.2c00096] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang Z, Wang Y, Chen X, Song X, Tu Z, Chen Y, Zhang Z, Ding K. Characterization of an aromatic trifluoromethyl ketone as a new warhead for covalently reversible kinase inhibitor design. Bioorg Med Chem 2021;50:116457. [PMID: 34670167 DOI: 10.1016/j.bmc.2021.116457] [Reference Citation Analysis]
11 Reja RM, Wang W, Lyu Y, Haeffner F, Gao J. Lysine-Targeting Reversible Covalent Inhibitors with Long Residence Time. J Am Chem Soc 2022. [PMID: 35040658 DOI: 10.1021/jacs.1c12702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Zheng J, Zhang W, Li L, He Y, Wei Y, Dang Y, Nie S, Guo Z. Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review. Front Chem 2022;10:860985. [DOI: 10.3389/fchem.2022.860985] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhong Z, Shi L, Fu T, Huang J, Pan Z. Discovery of Novel 7-Azaindole Derivatives as Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the Treatment of Hepatocellular Carcinoma. J Med Chem 2022. [PMID: 35549181 DOI: 10.1021/acs.jmedchem.2c00255] [Reference Citation Analysis]
14 Nam Y, Shin I, Kim Y, Ryu S, Kim N, Ju E, Sim T. Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation. Neoplasia 2022;24:34-49. [PMID: 34864570 DOI: 10.1016/j.neo.2021.11.011] [Reference Citation Analysis]
15 Askey HE, Grayson JD, Tibbetts JD, Turner-Dore JC, Holmes JM, Kociok-Kohn G, Wrigley GL, Cresswell AJ. Photocatalytic Hydroaminoalkylation of Styrenes with Unprotected Primary Alkylamines. J Am Chem Soc 2021;143:15936-45. [PMID: 34543004 DOI: 10.1021/jacs.1c07401] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Turner LD, Trinh CH, Hubball RA, Orritt KM, Lin CC, Burns JE, Knowles MA, Fishwick CWG. From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor. J Med Chem 2021. [PMID: 34780700 DOI: 10.1021/acs.jmedchem.1c01163] [Reference Citation Analysis]
17 Zhang Z, Li J, Chen H, Huang J, Song X, Tu ZC, Zhang Z, Peng L, Zhou Y, Ding K. Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors. J Med Chem 2022. [PMID: 35119278 DOI: 10.1021/acs.jmedchem.1c01816] [Reference Citation Analysis]
18 Pan C, Nie W, Wang J, Du J, Pan Z, Gao J, Lu Y, Che J, Zhu H, Dai H, Chen B, He Q, Dong X. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors. Eur J Med Chem 2021;225:113794. [PMID: 34488024 DOI: 10.1016/j.ejmech.2021.113794] [Reference Citation Analysis]
19 Ryu S, Nam Y, Kim N, Shin I, Jeon E, Kim Y, Kim ND, Sim T. Identification of Pyridinyltriazine Derivatives as Potent panFGFR Inhibitors against Gatekeeper Mutants for Overcoming Drug Resistance. J Med Chem 2022. [PMID: 35436119 DOI: 10.1021/acs.jmedchem.1c01776] [Reference Citation Analysis]